Demand for services such as pharmaceutical research and development is picking up along with the acceleration of BD for innovative drugs going overseas. Recently, a number of CXO listed companies said at the third quarter results briefing that the company has plenty of orders in hand, and the annual performance is expected to grow. As the scale of project delivery in the fourth quarter expands further, the industry boom is expected to continue. Orient Securities recently released a research report stating that in the first three quarters of 2026, the CXO industry performed outstanding and the industry trend was improving. According to the data, the CRO/CMO sector's revenue in the first three quarters increased 24.5% year on year, and net profit after deducting non-return to mother increased 57.6% year on year. Overall, the promotion of overseas marketing and commercialization of innovative drugs is expected to continue to drive R&D and production demand, and support profit growth in the CRO/CMO and chemical pharmaceutical sectors.

Demand for services such as pharmaceutical research and development is picking up along with the acceleration of BD for innovative drugs going overseas. Recently, a number of CXO listed companies said at the third quarter results briefing that the company has plenty of orders in hand, and the annual performance is expected to grow. As the scale of project delivery in the fourth quarter expands further, the industry boom is expected to continue. Orient Securities recently released a research report stating that in the first three quarters of 2026, the CXO industry performed outstanding and the industry trend was improving. According to the data, the CRO/CMO sector's revenue in the first three quarters increased 24.5% year on year, and net profit after deducting non-return to mother increased 57.6% year on year. Overall, the promotion of overseas marketing and commercialization of innovative drugs is expected to continue to drive R&D and production demand, and support profit growth in the CRO/CMO and chemical pharmaceutical sectors.